EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cognitive impairment associated with MAPK inhibition in colorectal cancer

E. Gevorkyan, A. Bobrov, N. Semenova, L. Vladimirova

European Psychiatry · 2026-06 · 69 (S1) · S780-S780

DOI: 10.1192/j.eurpsy.2026.11544 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Psychiatry, online erschienen am 31.07.2026. Verfasst von E. Gevorkyan und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Targeted therapy significantly improves survival in metastatic colorectal cancer (mCRC). However, its neuropsychiatric side effects remain poorly understood. The mitogen-activated protein kinase (MAPK) cascade plays a crucial role in synaptic plasticity and memory formation; therefore, its inhibition through targeted therapy, including EGFR blockade, is a matter of interest for studying patients with mCRC.

Objectives

This study aimed to evaluate the impact of anti-EGFR-targeted therapy, compared with anti-VEGF-targeted therapy, on cognitive performance in patients with stage IV colorectal cancer.

Methods

Eighty patients with mCRC were enrolled. The main group (n = 55) received FOLFOX6 combined with an anti-EGFR monoclonal antibody (cetuximab or panitumumab), which inhibits the MAPK cascade. The control group (n = 25) received FOLFOX6 plus bevacizumab, which does not affect the MAPK cascade. Cognitive status was assessed at baseline and after 3–4 months using the Addenbrooke’s Cognitive Examination-Revised (ACE-R) and the Frontal Assessment Battery (FAB).

Results

At baseline, cognitive scores were comparable between groups. After 3–4 months, the anti-EGFR targeted group showed a marked decline in ACE-R total scores from 94[90; 95] to 86[85; 90] (p = 0.001), whereas the control group remained stable (94[91; 97] to 94[90; 96]; p> 0.05). Memory scores declined in the anti-EGFR group from 22[22; 24] to 19[19; 20] (p= 0.001), while the control group showed only a mild reduction (23[21; 26] to 22[21; 25]; p= 0.034). Attention/orientation also decreased in the anti-EGFR group (18[16; 18] to 17[15; 18]; p= 0.024), but remained unchanged in controls (18[18; 18] throughout). Other ACE-R domains and FAB subscores demonstrated no significant changes.

Conclusions

Anti-EGFR-targeted therapy, which involves inhibiting the MAPK cascade, is found to be associated with selective cognitive impairment, predominantly affecting memory and attention. Regular cognitive monitoring may support timely psychiatric referral, optimize management strategies, and ultimately improve patients’ quality of life. Disclosure of Interest None Declared

Zitieren

APA

Gevorkyan, E., Bobrov, A., Semenova, N., & Vladimirova, L. (2026). Cognitive impairment associated with MAPK inhibition in colorectal cancer. European Psychiatry, 69(S1), S780-S780. https://doi.org/10.1192/j.eurpsy.2026.11544

Vancouver

Gevorkyan E, Bobrov A, Semenova N, Vladimirova L. Cognitive impairment associated with MAPK inhibition in colorectal cancer. European Psychiatry. 2026;69(S1):S780-S780. doi:10.1192/j.eurpsy.2026.11544

BibTeX
@article{Gevorkyan2026,
  author = {Gevorkyan, E. and Bobrov, A. and Semenova, N. and Vladimirova, L.},
  title = {Cognitive impairment associated with MAPK inhibition in colorectal cancer},
  journal = {European Psychiatry},
  year = {2026},
  volume = {69},
  number = {S1},
  pages = {S780--S780},
  doi = {10.1192/j.eurpsy.2026.11544}
}
Kostenlos starten →